|

Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes

RECRUITINGEarly 1Sponsored by Anna Stanhewicz, PhD
Actively Recruiting
PhaseEarly 1
SponsorAnna Stanhewicz, PhD
Started2024-09-11
Est. completion2027-12-31
Eligibility
Age18 Years – 45 Years
SexFEMALE
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT05917587

Summary

The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease.

Eligibility

Age: 18 Years – 45 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* ≥12 weeks and ≤5 years postpartum
* history of GDM or healthy pregnancy

Exclusion Criteria:

* prediabetes or diabetes (HbA1c ≥5.7%)
* current tobacco use
* cardiovascular or metabolic disease
* cardiovascular or metabolic medication
* history of hypertension during pregnancy
* current pregnancy

Conditions2

DiabetesGestational Diabetes

Locations1 site

University of Iowa
Iowa City, Iowa, 52242
Anna Stanhewicz, PhD319-467-1732anna-stanhewicz@uiowa.edu

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.